Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea

Exclusion Criteria

• •Treatment with sequestrants within one week before the SeHCAT.
• •Treatment with any constipants/laxatives one day before the SeHCAT, with the exception of opioids, if the dosis has been stable in the prior 2 weeks.
• •Pregnancy, screening by pregnancy test before inclusion.
• •Breastfeeding women.
• •Small bowel resection, including right sided hemicolectomy.
• •Any ongoing treatment for inflammatory bowel disease with systemic steroids (i.e. budesonide or prednisone) or treatment in the prior 4 weeks.
• •Allergies to constituents of Xenbilox: (chenodeoxycholic acid, cornflour, magnesium stearate, highly dispersed silica, gelatine, sodium dodecylsulphate, titanium dioxide (E171), quinolone yellow (E104), erythrosine (E127)
• •Chronic or acute cholecystitis.
• •Liver cirrhosis,
• •Obstructed bile flow causing jaundice or elevated p-bilirubin (\> 1,5 UNL).
• •Known disability in gall bladder contractility.
• •Bile duct atresia.
• •Frequent gallstone attacks (\>2/month).